Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407S6 | ISIN: US60855D3098 | Ticker-Symbol: MOL
Lang & Schwarz
05.06.25 | 07:00
0,800 Euro
-100,00 % -0,800
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULIN BIOTECH INC Chart 1 Jahr
5-Tage-Chart
MOLECULIN BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7900,81007:00

Aktuelle News zur MOLECULIN BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMoleculin Biotech, Inc.: Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)158Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement...
► Artikel lesen
MiMoleculin Biotech, Inc. - 8-K, Current Report2
MoMoleculin Biotech files to sell 10.99M shares of common stock, warrants1
MoMoleculin Biotech, Inc. - S-1, General form for registration of securities1
23.05.Moleculin Biotech, Inc. - 8-K, Current Report12
14.05.Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved8
MOLECULIN BIOTECH Aktie jetzt für 0€ handeln
14.05.Moleculin Biotech GAAP EPS of -$0.694
14.05.Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update86Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports...
► Artikel lesen
13.05.Moleculin Biotech, Inc. - 10-Q, Quarterly Report1
12.05.Moleculin erweitert EU-Studie für Leukämie-Behandlung3
12.05.Moleculin expands EU trial for leukemia treatment3
12.05.Moleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial619Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE"...
► Artikel lesen
12.05.Moleculin Biotech, Inc. - 8-K, Current Report5
06.05.Moleculin Biotech, Inc.: Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin4
06.05.USPTO grants two additional patents to Moleculin's drug candidate1
05.05.Moleculin Biotech, Inc.: Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents1
05.05.Moleculin Biotech, Inc. - 8-K, Current Report1
30.04.Moleculin Biotech, Inc. - 10-K/A, Annual Report2
29.04.Moleculin reports Annamycin cancer drug synergy at AACR meeting1
29.04.Moleculin Biotech, Inc.: Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer141Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically...
► Artikel lesen
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1